Find Canertinib manufacturers, exporters & distributors on PharmaCompass

Canertinib

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

1INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 267243-28-7, Ci-1033, Pd-183805, Canertinib (ci-1033), Canertinib free base, N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

Molecular Formula

C₂₄H₂₅ClFN₅O₃

Molecular Weight

485.9 g/mol

InChI Key

OMZCMEYTWSXEPZ-UHFFFAOYSA-N

FDA UNII

C78W1K5ASF

Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

1 2D Structure

Canertinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide

2.1.2 InChI

InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)

2.1.3 InChI Key

OMZCMEYTWSXEPZ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

2.2 Other Identifiers

2.2.1 UNII

C78W1K5ASF

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Ci 1033

2. Ci-1033

3. Ci1033

2.3.2 Depositor-Supplied Synonyms

1. 267243-28-7

2. Ci-1033

3. Pd-183805

4. Canertinib (ci-1033)

5. Canertinib Free Base

6. N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

7. N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide

8. C78w1k5asf

9. Chembl31965

10. N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide

11. Chebi:61399

12. 267243-28-7 (free Base)

13. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide

14. Ncgc00182713-01

15. Pd183805

16. Canertinib [inn]

17. Canertinib [inn:ban]

18. Sn-26606

19. Ci-1033(canertinib)

20. Ci1033

21. Unii-c78w1k5asf

22. Canetinib

23. Canertinib [mi]

24. Caneritinib; Ci-1033

25. Canertinib - Ci-1033

26. Ci-1033 (canertinib)

27. Canertinib [who-dd]

28. Dsstox_cid_28869

29. Dsstox_rid_83138

30. Dsstox_gsid_48943

31. Schembl54837

32. Mls004774146

33. Pd 183805 Dihydrochloride

34. Bdbm4779

35. Cid_156414

36. Gtpl5675

37. Dtxsid8048943

38. Ex-a078

39. Bcpp000301

40. Hms3244m17

41. Hms3244m18

42. Hms3244n17

43. Bcp01790

44. Tox21_113361

45. Nsc780019

46. Nsc801011

47. S1019

48. Zinc27439698

49. Akos005145818

50. Bcp9000481

51. Bcp9000482

52. Bcp9000525

53. Ccg-269588

54. Cs-0121

55. Db05424

56. Nsc-780019

57. Nsc-801011

58. Sb16594

59. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

60. N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]prop-2-enamide

61. Ncgc00182713-02

62. Ncgc00182713-18

63. As-56189

64. Hy-10367

65. Smr003500789

66. Pd0183805

67. Cas-267243-28-7

68. Ft-0654215

69. Ec-000.2258

70. A25038

71. 499c452

72. Q5032274

73. 2-propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-

74. N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide

75. N-[4-(3-chloro-4-fluoro-phenyl-amino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₅ClFN₅O₃
Molecular Weight	485.9 g/mol
XLogP3	3.9
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	9
Exact Mass	485.1629955 g/mol
Monoisotopic Mass	485.1629955 g/mol
Topological Polar Surface Area	88.6 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	671
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in breast cancer and lung cancer.

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.

INTERMEDIATES SUPPLIERS